Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

L Happe; Stephanie Earnshaw; C Walko; K Richards; G Fang; M Ward

Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward, M., Fang, G., Richards, K., Walko, C., Earnshaw, S., & Happe, L. (2015). Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. Journal of Health Economics, 2(2), 181-91.

Copy citation

Recent Publications

Article

The evolution of minimally invasive tissue sampling in postmortem examination

Article

Accountability for SRHR in the context of the COVID-19 pandemic

Article

Validation of simple dichotomous self-report on prenatal alcohol and other drug use in women attending midwife obstetric units in the Cape Metropole, South Africa

Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Publications Info

Meet the Experts

Stephanie Earnshaw

Recent Publications

Article

The evolution of minimally invasive tissue sampling in postmortem examination

Article

Accountability for SRHR in the context of the COVID-19 pandemic

Article

Validation of simple dichotomous self-report on prenatal alcohol and other drug use in women attending midwife obstetric units in the Cape Metropole, South Africa

Article

Nicotinic acetylcholine receptor accessory subunits determine the activity profile of epibatidine derivatives